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rats received lanthanum carbonate in their food, not by
gavage like in the study by Behets et al [2]. Neverthe-
less, lanthanum tissue concentrations found in our study
were of same order of magnitude as those of the latter
study. Thus, the mean bone lanthanum content was near
300 ng/g (lg/kg) wet weight in the lanthanum carbonate-
overloaded uremic rats of our study and near 1500 lg/kg
wet weight in their lanthanum carbonate-overloaded ure-
mic rats. One has to consider that the animals of our study
ingested approximately 1800 mg/kg lanthanum carbonate
per day for a time period of only 4 weeks, whereas the
rats of their study were gavaged with a maximal daily
dose of 1000 mg/kg lanthanum carbonate for a time pe-
riod of 3 months. When correcting for this time factor,
it is fair to conclude that the measurements in the two
studies yielded comparable results. The lanthanum mea-
surement techniques were the same, namely, inductively
coupled plasma emission spectrometry.
McLeod et al point out that they and others routinely
differentiate plasma lanthanum concentrations measured
in lanthanum-treated groups from those determined
in control samples. They show Figure 1 demonstrating
plasma lanthanum concentrations before and after an
acute dose of lanthanum carbonate given to rats. How-
ever, when analyzing Figure 1 closely, it becomes ap-
parent that the plasma lanthanum concentration (near
350 lg/L) found 24 hours after the acute dose was prob-
ably not different from the lanthanum concentration in
control plasma samples. Note that the latter was below
the lower limit of quantification. In the rats of our study,
lanthanum carbonate was not given as an acute load, but
was ingested progressively during 24 hours. Therefore,
one would not expect a peak plasma concentration such
as the one shown in McLeod et al’s figure, but rather a
concentration near to the bottom line. This is exactly what
we found (200-500 lg/L).
In our opinion, the suspicion of sample contamination
that has been formulated based on a typographic error in
one of the figures of our article can be ruled out with a
reasonable degree of confidence.
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Lanthanum pharmacokinetics:
Are rat data misleading?
To the Editor: On the basis of higher urine lanthanum
recoveries in uremic rats, Lacour et al [1] conclude there
are “important differences in the pharmacokinetics of
lanthanum in chronic renal failure.” This seems not to
be the case in man. Indeed, in a series of Phase I stud-
ies carried out to support the development of Fosrenol,
plasma concentration versus time profiles, and pharma-
cokinetic parameters (Cmax, AUC0−t, t1/2 abs, and t1/2 elim)
were similar in healthy subjects and dialysis patients (see
Fig. 1, p. 2908) [2], excluding a significant role of the kid-
ney in the elimination of lanthanum and suggesting little
influence of end-stage renal disease (ESRD) on systemic
bioavailability. It is possible that higher absorption and,
hence, higher portal plasma and liver lanthanum concen-
trations may occur in renal failure without affecting sys-
temic plasma profiles, but no data are available on this at
the present time.
Sample contamination may have influenced the Lacour
et al [1] rat data, as plasma lanthanum concentrations
in the controls in this study were extremely high com-
pared to other studies [3]. Inevitably, there is contact be-
tween urine, feces, and spilled diet in standard rodent
metabolism cages and, hence, an opportunity exists for
the high concentrations of lanthanum present in diet and
feces to transfer to urine. The extent of contamination will
be proportional to the volume of urine washing over cage
surfaces and, as Lacour et al [1] highlight, urine volume
was markedly elevated in the uremic groups. Such con-
tamination is a common source of error in rat excretion
studies, particularly when poorly absorbed drugs, present
at very low concentrations (nmol/L) in body tissues and
fluids, are administered via the diet [4]. The potential for
contamination can be reduced by controlled gavage of
the drug directly into the stomach of the rats.
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LAM-IV-110 Healthy volunteers with food (N = 35)
LAM-IV-110 Healthy volunteers after food (N = 35)
LAM-IV-111 Healthy volunteers (N = 8)
SPD405-117 Healthy volunteers (N = 8)
LAM-IV-111 Dialysis patients (N = 9)
Fig. 1. Mean plasma lanthanum concentra-
tion profiles in healthy volunteers and dial-
ysis patients after a single oral dose of lan-
thanum carbonate (Fosrenol; 4 × 250-mg
chewable tablets) in Phase I clinical stud-
ies. Study LAM-IV-110: Phase I, open-label,
randomized, 2-way crossover study compar-
ing lanthanum carbonate administered dur-
ing, and after food in healthy subjects. Study
LAM-IV-111: Phase I, open-label, single- and
multiple-dose study comparing lanthanum
pharmacokinetics in dialysis patients and
healthy subjects. Study SPD405-117: single-
dose, open-label, parallel group study to as-
sess lanthanum pharmacokinetics after oral
and intravenous dosing in healthy male sub-
jects. Poster presentation at ASN 2003 [5], full
publications in preparation.
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Reply from the Authors
D’Haese et al take issue with our statement that there
are important differences in the pharmacokinetics of lan-
thanum in chronic renal failure (CRF), compared with
the normal state. This statement was based on our finding
of a significantly higher degree of tissue lanthanum accu-
mulation in CRF rats than in rats with normal renal func-
tion in response to high oral lanthanum doses, as reported
in a recent issue of Kidney International [1]. Authors state
that plasma lanthanum kinetics after an acute oral dose
of lanthanum carbonate were similar in healthy subjects
and dialysis patients. However, on closer scrutiny of their
Figure, it is clear that only the LAM-IV-III study deals
with this issue. The other three kinetics studies are not
directly related. Surprisingly, the plasma kinetics of the
healthy volunteers and the dialysis patients in the LAM-
IV-III study look quite different, with markedly higher
plasma lanthanum concentrations over time in the latter
and no overlap. Moreover, even if there was no signifi-
cant difference between the healthy and uremic subjects
in response to an acute oral lanthanum dose, this does not
exclude the possibility of enhanced tissue accumulation
of lanthanum in the uremic state after long-term adminis-
tration. Increased intestinal absorption is almost certainly
involved in the enhanced tissue lanthanum accumulation
associated with the uremic state. This can be deduced
from our observation of a significantly higher urinary lan-
thanum excretion in the 5/6 nephrectomy model of CRF
rats, together with an increase in lanthanum content in
various tissues [1].
Sample contamination can be reasonably excluded
because we found lanthanum concentrations in bone
tissue comparable to those reported for CRF rats by
the Antwerp group [2]. Of note, if contamination by
lanthanum contained in food played an important role,
this should have led to a similar increase of urinary
lanthanum excretion in non-CRF as in CRF rats be-
cause these two groups of animals were exposed to
same lanthanum-enriched diet. This is, in our opin-
ion, another strong argument against the contamination
hypothesis.
The fact that the Antwerp group administered lan-
thanum carbonate by gavage at daytime [2] probably ex-
plains why they failed to observe a significant reduction
in plasma phosphorus because rats eat only during night-
time. Instead, our mode of administering lanthanum car-
bonate together with the diet almost certainly explains
why we were able to observe a significant phosphorus-
lowering effect because the animals ingested the phos-
phate binder together with their meals. As to the very
high plasma lanthanum levels reported in the rats of our
study, regrettably these are due to a transcription error
of the units transmitted by the laboratory. They should
read lg/L instead of lg/mL, as outlined in more detailed
fashion in our reply to McLeod et al.
Finally, we feel that studies in animals are useful to
anticipate possible problems with new drugs before their
widespread administration to human beings.
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